866-997-4948(US-Canada Toll Free)

Germ Cell Tumors Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Oncology

No. of Pages : 143 Pages


Germ Cell Tumors Pipeline Review, H2 2012

Global Markets Directs, 'Germ Cell Tumors Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Germ Cell Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Germ Cell Tumors. Germ Cell Tumors Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Germ Cell Tumors.
  • A review of the Germ Cell Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Germ Cell Tumors pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Germ Cell Tumors.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Germ Cell Tumors pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 9
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Germ Cell Tumors Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Germ Cell Tumors 12
Germ Cell Tumors Therapeutics under Development by Companies 14
Germ Cell Tumors Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Germ Cell Tumors Therapeutics Products under Development by Companies 22
Germ Cell Tumors Therapeutics Products under Investigation by Universities/Institutes 23
Companies Involved in Germ Cell Tumors Therapeutics Development 27
ARQULE, INC 27
Germ Cell Tumors Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
tivantinib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Etoposide + Cisplatin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Paclitaxel + Ifosfamide + Carboplatin + Filgrastim + Autologous Stem Cell Transplantation - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Vincristine + Irinotecan + Temozolomide + Bevacizumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 39
Abraxane + Lapatinib - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
sunitinib malate - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Carmustine + Cyclophosphamide + Etoposide + Autologous Stem Cell Transplantation - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Etoposide + Carboplatin + Autologous Stem Cell Transplantation - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Epirubicin + Taxol + Thiotepa + Etoposide + Ifosfamide + Carboplatin + Autologous Stem Cell Transplantation - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 78
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Ifosfamide + Vinblastine + Autologous Bone marrow Transplantation - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Bevacizumab + Gemcitabine + Docetaxel + Melphalan + Carboplatin + Stem Cell Transplantation - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 82
Bleomycin + Etoposide + Platinum - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
MLN-8237 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
K562-GM Vaccine + Cyclophosphamide + Celecoxib - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
VP-16213 + Carboplatin + Autologous Bone Marrow Transplantation - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
everolimus - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Filgrastim + Pegfilgrastim + Carboplatin + Cisplatin + Dexamethasone + Etoposide + Ifosfamide + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 90
Carboplatin + Etoposide + Thiotepa + Filgrastim + Stem Cell Transplantation - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 92
Filgrastim + Carboplatin + Etoposide + Ifosfamide + Paclitaxel + Autologous Bone Marrow Transplantation - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Pegfilgrastim + Cisplatin + Ifosfamide + Paclitaxel - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Oxaliplatin + Paclitaxel - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Dasatinib + Ifosfamide + Carboplatin + Etoposide - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 98
Aprepitant + 5HT3 + Dexamethasone - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
talabostat + carboplatin - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
talabostat + temozolomide - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Allogeneic Tumor Cell Vaccine + Iscomatrix + Celecoxib + Cyclophosphamide - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Cisplatin + Gemcitabine + Paclitaxel - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 107
Cisplatin + Paclitaxel + Gemcitabine - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 109
Dactinomycin + Filgrastim + Carboplatin + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Leucovorin calcium + Methotrexate + Vincristine sulfate - Drug Profile 110
Product Description 110
Mechanism of Action 111
R&D Progress 112
Filgrastim + Pegfilgrastim + Yondelis - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
ABT-751 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
ABT-751 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Sirolimus + Celecoxib + Etoposide + Cyclophosphamide - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
Carboplatin + Etoposide + Stem Cell Transplantation + Autologous Bone Marrow Transplantation - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Carboplatin + Etoposide + Local Irradiation - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Carboplatin + Cisplatin + Dexamethasone + Etoposide + Ifosfamide + Filgrastim + Pegfilgrastim + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 124
PD-0332991 - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
Bevacizumab + Carboplatin + Mesna + Ifosfamide + Etoposide + Stem Cell Transplantation - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 127
Etoposide + Carboplatin + Cyclophosphamide + Mesna + Melphalan + Tandem Peripheral Blood Stem Cell - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 129
temozolomide - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Paclitaxel + Gemcitabine - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
Carboplatin + Gemcitabine Hydrochloride - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
Germ Cell Tumors Therapeutics Drug Profile Updates 134
Germ Cell Tumors Therapeutics Discontinued Products 136
Germ Cell Tumors Therapeutics - Dormant Products 137
Germ Cell Tumors Product Development Milestones 140
Featured News & Press Releases 140
Nov 14, 2011: ZIOPHARM Oncology Announces Promising Data From Phase Ib Study Of Palifosfamide In Small Cell Lung And Other Cancers At AACR-NCI-EORTC Meeting 140
May 31, 2008: Amgen Announces Interim Phase 2 Results Of Denosumab In Cell Tumor of Bone 140

Appendix 142
Methodology 142
Coverage 142
Secondary Research 142
Primary Research 142
Expert Panel Validation 142
Contact Us 143
Disclaimer 143

List of Table


Number of Products Under Development for Germ Cell Tumors, H2 2012 12
Products under Development for Germ Cell Tumors Comparative Analysis, H2 2012 13
Number of Products under Development by Companies, H2 2012 14
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 18
Comparative Analysis by Late Stage Development, H2 2012 19
Comparative Analysis by Mid Clinical Stage Development, H2 2012 20
Comparative Analysis by Early Clinical Stage Development, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 24
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 25
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 26
ARQULE, INC, H2 2012 27
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 33
Germ Cell Tumors Therapeutics Drug Profile Updates 134
Germ Cell Tumors Therapeutics Discontinued Products 136
Germ Cell Tumors Therapeutics Dormant Products 137

List of Chart


Number of Products under Development for Germ Cell Tumors, H2 2012 12
Products under Development for Germ Cell Tumors Comparative Analysis, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Late Stage Products, H2 2012 19
Mid Clinical Stage Products, H2 2012 20
Early Clinical Stage Products, H2 2012 21
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *